



## R-CHOP 14 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma, cycle 1-6

Protocol-ID: 112 V1.1 (Basic), R-CHOP 14 (RITU375/CYCL750/DOXO50/VNCR2/PRED100), DLBCL, C1-6

### Indication(s)

- NHL, B-Cell Type, Diffuse Large Cell; ICD-10 C83.3
- NHL, B-Cell Type, Follicular grade IIIb; ICD-10 C82.-, C82.7, C82.9

### Cycles

Cycle length 14 days, recommended cycles: 6

### Protocol sequences

- [R-CHOP 14 \(RITU375/CYCL750/DOXO50/VNCR2/PRED100\), DLBCL, C1-6 \(PID112\) -|- RITU375, C7-8 \(PID1448\)](#)

### References

- Pfreundschuh M, Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). *Lancet Oncol* 2008 Feb;9(2):105-16. doi: 10.1016/S1470-2045(08)70002-0. PMID: 18226581. [[PMID](#)]
- Brusamolino E, Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. *Haematologica* 2006 Apr;91(4):496-502. PMID: 16537117. [[PMID](#)]
- Cunningham D, Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. *Lancet* 2013 May 25;381(9880):1817-26. doi: 10.1016/S0140-6736(13)60313-X. PMID: 23615461. [[PMID](#)]

### Recommendations

- 10/2015: [European Society for Medical Oncology](#)
- 05/2021: [National Comprehensive Cancer Network](#)

### Important notice

The copyrighted protocols are treatment recommendations. The information contained in this compilation on cytostatic drugs, concomitant medication and other therapeutic procedures, as well as dosage and application information, is continuously reviewed with all due care by the authors and editors involved. Nevertheless, the publishers and authors do not assume any liability for the correctness - also with regard to possible printing errors.

The protocols may not be changed in terms of content.

Diagnosis, indication for therapy and treatment of malignant diseases must be carried out in each individual case by the hematologist and oncologist on his or her own responsibility. The treating physician is obligated to this personal responsibility to weigh in each case before a diagnostic or therapeutic measure, indication, contraindications, dosage and application under consideration of the specialized information or other documents of the manufacturers. This applies in particular to rarely used preparations or preparations that are new to the market.



The publishers and authors assume no liability for the accuracy of the contents. The application is at the own responsibility of the treating physician. ©Onkopti.

Valid since: 19.01.2015